Biogen shares slip after mixed Phase 2 Alzheimer’s data, but analysts remain optimistic on diranersen’s cognitive benefits.
Importance Rank:
1
Biogen shares slip after mixed Phase 2 Alzheimer’s data, but analysts remain optimistic on diranersen’s cognitive benefits.